John Henneman

NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.

Alafair Biosciences, Inc. operates as a medical device company. It develops novel suite of products based on a non-cell adhesive hydrogel technology that protects and manages advanced wound healing. The firm addresses problems of wound healing and scar prevention with natural, animal-free biopolymer based products that are biocompatible, bioresorbable and hydrate injured tissues throughout healing. The company was founded by Daniel L. Peterson, John D. Joyoprayitno and Sarah Mayes in 2011 and is headquartered in Austin, TX.

SeaSpine Holdings Corp. operates as a medical technology company. The firm engages in the design, developmen and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. It products include thoracolumbar hardware, cervical hardware, orthobiologics, and spine pure strip. The company was founded on February 12, 2015 and is headquartered in Carlsbad, CA.